Concepedia

Sattva S. Neelapu

SS

Statistics

Publications

284

Citations

33K

H-Index

74

Active since

2001

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Moffitt Cancer Center

Stanford University

Dana-Farber Cancer Institute

Mayo Clinic in Arizona

Sattva S. Neelapu is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and cancer immunotherapy.

ORCID

Publications per year

2001–2025

284

Publications

284

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.9K citations · Full text

, , +16

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson et al. · The Lancet Oncology · 2018 · 2.3K citations

, , +12

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Enli Liu, David Marín, Pinaki P. Banerjee et al. · New England Journal of Medicine · 2020 · 2.1K citations · Full text

, , +17

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Michael Crump, Sattva S. Neelapu, Umar Farooq et al. · Blood · 2017 · 1.7K citations · Full text

, , +10

Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions

Yeonseok Chung, Shinya Tanaka, Fuliang Chu et al. · Nature Medicine · 2011 · 1.1K citations · Full text

, , +14

1–5 of 284